Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results , with sales up 6.8% year on year to $15.62 billion ...

"If you have chronic lung disease, even asthma ... losing out on work," Heather Platt, Merck's product development team lead for the newly cleared vaccine, told CNBC in an interview.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

and according to Merck has the potential to become a $3 billion product at peak for PAH, thanks to its to become the first drug for PAH that addresses the underlying disease process rather than ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

The table below is a review of notable updates that occurred in December 2024 for investigational products in development ... with type 1 diabetes and chronic kidney disease.

Shares of Merck are sliding in early trading after ... due partly to a pause in shipments of one of its top-selling products to China Shares of Merck slid Tuesday after the drugmaker surprised ...